Medical experts are endorsing KISQALI as their preferred CDK4/6 inhibitor for appropriate patients with early (stage II/III at high risk of recurrence) or metastatic HR+/HER2- breast cancer, in combination with an AI
National Comprehensive Cancer Network® (NCCN®) differentiates ribociclib (KISQALI®) as the first and only Category 1 Preferred treatment option when used in combination with an AI for appropriate patients with HR+/HER2- mBC in 1L and for appropriate patients with HR+/HER2- eBC, including those with high-risk node-negative disease.1
In HR+/HER2- eBC, high-risk node-negative disease is defined as either tumor size >5 cm, or if tumor size 2-5 cm, either grade 2 (with high genomic risk or Ki-67 ≥20%), or grade 3.1,2
There is controversy on the choice of CDK4/6i as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.1
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.1
1L, first line; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
There is controversy on the choice of CDK4/6i as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.1
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.1
1L, first line; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
Take a closer look at NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer: Download the clinical flashcard
More of your peers are prescribing KISQALI than ever before
KISQALI is the #1 prescribed CDK4/6 inhibitor in new-to-brand prescriptions in both HR+/HER2- eBC and mBC
January 2025 IQVIA custom breast cancer market sizing report.
Reference: Data on file. mBC and eBC NBRx share data from IQVIA market sizing report. Novartis Pharmaceuticals Corp; 2025.
Reference: Data on file. mBC and eBC NBRx share data from IQVIA market sizing report. Novartis Pharmaceuticals Corp; 2025.
See what KISQALI could mean for the patients in your practice
NCCN Guidelines: A Clinical Flashcard
A closer look at some of the NCCN Guidelines® for Breast Cancer.
KISQALI Starter Guide
This guide provides assessment, dosing, and access and support information to help you get your patients started on their treatment with KISQALI.
KISQALI Access Support Guide
A guide to support patients during the insurance coverage process for KISQALI.